Becker's Healthcare October 30, 2024
A recent study revealed a 17.5% increase in asthma-related hospitalizations in the three months following the announcement that GSK would discontinue the widely used asthma medication Flovent, and 24.1% in the following three to six months, ABC News reported Oct. 30.
The research, conducted by EPIC Research, analyzed data from over 3 million patients and highlighted the potential risks associated with the switch to alternative medications.
Five-year-old Burton Hayes, whose asthma was previously well managed on Flovent, faced significant health challenges after his mother was forced to...
Today's Sponsors
Today's Sponsor